WELCOME!

Staying Connected

We’re pleased to announce that in these uncertain times, the Symposium will still be going ahead with all the elements our community has come to expect, but with one key difference – we’re moving online! The virtual format has many benefits for our participants, sponsors, exhibitors and speakers – more details below.

Hosted By

The Australasian Wound & Tissue Repair Society (AWTRS) and the Matrix Biology Society of Australia and New Zealand (MBSANZ) are two leading scientific societies focused on the fundamental biological and biochemical mechanisms involved in wound healing and tissue repair and their application in the clinic, as well as the roles of the extracellular matrix in biology and pathology.

It is with great pleasure that we announce that the 12th Pan Pacific Connective Tissue Societies Symposium in conjunction with the scientific meetings of the AWTRS and MBSANZ will be held in November 2020. 

This website will be kept up to date with all the latest news about the symposium program, speakers, registration, abstract submission and much more, so please bookmark this page for future reference. We very much look forward to welcoming you to our virtual event in November 2020.

The PPCTSS 2020 Organising Committee zoom into action

Virtual Conference Details

In the new world we all find ourselves in, the virtual format offers a number of significant advantages over traditional face to face meetings. Paramount of course is the safety of everyone involved in the meeting, but our dedicated online events platform has many other features, including:

  • A significant reduction in registration fees – especially important when so many organisations are facing serious budgetary constraints
  • Live streaming of all oral presentations, including international plenary speakers, with live Q and A at the end of each session
  • Interactive poster sessions, with poster presenters able to chat in real time with delegates interested in their work
  • Live networking sessions where attendees can discuss areas of mutual interest, set up one-on-one video chats, or introduce colleagues to others
  • Exhibition booths hosted by exhibitors who can showcase their latest products, arrange live demonstrations, answer questions and provide supporting material – all in real time!
  • The same exciting range of topics and research areas, all presented in online formats compatible with traditional presentation methods
  • The opportunity for Q and A with speakers outside of the online sessions – no more running out of time for questions!
  • The abstract submission, review and notification process will remain essentially unchanged
  • The opportunity to reach a far wider audience by removing constraints such as travel, accommodation and time
  • Online archiving of all material available for access by members

The Symposium will take place over 24 – 26 November 2020 and the timing of the sessions will be adjusted to suit the virtual format and accommodate time differences for international speakers. Of course, if you have any questions at all about how the virtual meeting will run please don’t hesitate to contact us.

Featured Speaker Profile

Today’s featured speaker is:

Dr Shenda Baker

Dr Shenda Baker is the President and CEO of Synedgen, a biotech company creating glycopolymer solutions for injury, infection and inflammation at mucosal and dermal surfaces. Dr Baker’s research interests include chemical modification of biologically derived polyglucosamines and targeted interactions of glycopolymers to control innate immunity, tissue regeneration, inflammation, infection, cell protection and fibrosis. In particular, Synedgen’s work focuses on replacement of barrier function and anti-inflammatory activity due to the loss of mucins and the regular glycocalyx in physical, chemical or radiation-induced damage. Dr Baker has led the development of FDA cleared medical devices for managing complex wounds and burns and for oral health including xerostomia and oral mucositis. She also brought an inhaled pulmonary treatment for infection and inflammation in cystic fibrosis patients through Phase 1 clinical trials and guided the license of that program to Synspira Therapeutics. The current focus of Synedgen research is directed to treating radiation and chemotherapy damage of the gastrointestinal tract to improve patient outcomes in oncology.


Conference Chairs
Professor John Whitelock, University of New South Wales, Sydney
Dr Brooke Farrugia, The University of Melbourne

Organising Committee
A/Professor Larisa Haupt, Queensland University of Technology
A/Professor Pritinder Kaur, Curtin University
Dr Zlatko Kopecki, University of South Australia
A/Professor Megan Lord, University of New South Wales Sydney